Indegene Limited

NSE INDGN.NS

Indegene Limited EBITDA for the year ending March 31, 2024: USD 58.18 M

Indegene Limited EBITDA is USD 58.18 M for the year ending March 31, 2024, a 5.29% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Indegene Limited EBITDA for the year ending March 31, 2023 was USD 55.26 M, a 57.80% change year over year.
  • Indegene Limited EBITDA for the year ending March 31, 2022 was USD 35.02 M, a -1.50% change year over year.
  • Indegene Limited EBITDA for the year ending March 31, 2021 was USD 35.55 M, a 100.00% change year over year.
  • Indegene Limited EBITDA for the year ending March 31, 2020 was USD 17.78 M.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
NSE: INDGN.NS

Indegene Limited

CEO Mr. Manish Gupta BTech, MBA
IPO Date May 13, 2024
Location India
Headquarters Manyata Embassy Business Park
Employees 4,367
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.

StockViz Staff

January 16, 2025

Any question? Send us an email